𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo

✍ Scribed by Ingo Kausch; Anja Lingnau; Elmar Endl; Kirsten Sellmann; Irina Deinert; Timothy L. Ratliff; Dieter Jocham; Georg Sczakiel; Johannes Gerdes; Andreas Böhle

Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
317 KB
Volume
105
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The Ki‐67 protein is tightly regulated and depends on the proliferative status of a cell. It is present in the nuclei of proliferating cells but absent in resting cells. Since transformation of malignant cells is frequently associated with high cell proliferation and since proliferation is tightly associated with the Ki‐67 protein labeling index, this antigen may represent a potential target for cancer therapy. In the present study we determined the ability of a phosphorothioate antisense oligodeoxyribonucleotide (ODN) targeted against Ki‐67 mRNA to inhibit tumor cell proliferation specifically in cell culture, in multicellular 3‐dimensional spheroids (MCS) and in subcutaneous murine tumor models. Antisense treatment of 1 myeloid and different epithelial tumor cell lines in suspension and monolayer culture, respectively, resulted in specific reduction of Ki‐67 mRNA and protein, inhibition of proliferation and increased apoptotic cell death. Multicellular human bladder carcinoma spheroids lost their 3‐dimensional structure and underwent cell death after incubation with antisense oligonucleotides. The growth of subcutaneous syngeneic prostatic (p = 0.05) and transitional cell tumors (p = 0.001) in immunocompetent mice was significantly inhibited in antisense‐treated animals. From these findings we conclude that antisense inhibition of Ki‐67 protein expression may be a rational approach in anticancer therapy. © 2003 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

MAZ51, an indolinone that inhibits endot
MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo
✍ Vladimir Kirkin; Wilko Thiele; Petra Baumann; Ralph Mazitschek; Katrin Rohde; Gu 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 400 KB 👁 1 views

## Abstract We have recently described MAZ51, an indolinone that blocks the ligand‐induced autophosphorylation of VEGFR‐3, a receptor tyrosine kinase that plays a central role in the regulation of lymphangiogenesis. Here we show that MAZ51 is able to block the proliferation of VEGFR‐3‐expressing hu

In vitro and in vivo tumor growth inhibi
In vitro and in vivo tumor growth inhibition by a p16-mimicking peptide in p16INK4A-defective, pRb-positive human melanoma cells
✍ Douglas M. Noonan; Anna Severino; Monica Morini; Alessandra Tritarelli; Lucrezia 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

## Abstract The cell cycle regulatory pathway responsible for the control of the late‐G1 checkpoint is found recurrently altered in human malignant melanoma, often due to lack of functional p16 or pRb (pRb‐1) proteins. Here we examined the ability of p16‐derived peptides to mimic p16 function in tw

Recombinant antibody toxins specific for
Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo
✍ Marc Azemar; Mathias Schmidt; Friederike Arlt; Pierre Kennel; Burkhard Brandt; A 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 130 KB 👁 2 views

## Overexpression of the ErbB2 and epidermal growth factor receptor (EGFR) tyrosine kinases is frequently observed in squamous cell carcinomas of the head and neck, and has been correlated with shorter overall survival. By immunoblot analysis, we have found EGFR and ErbB2 expression in 6 out of 6 e